Results 211 to 220 of about 212,484 (305)

Toward Biology-Driven Surveillance After Endometrial Cancer Treatment: A Molecular-Clinical Framework Integrating Recurrence Phenotype. [PDF]

Cancers (Basel)
Szatkowski W, Glanowska-Nawrat I.
europepmc   +1 more source

Patterns of menopausal hormone therapy dispensing over 15 years—A Swedish register‐based cohort study

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
In this Swedish register‐based cohort study, systemic menopausal hormone therapy dispensing decreased over 15 years, while local therapy increased. Age, cohort effects, and sociodemographic characteristics were associated with differences in dispensing patterns.
Rebecca Götze Eriksson, Fanny Söderquist, Ge Bai, Per Wikman, Diego Hernan Giunta, Inger Sundström Poromaa, Evangelia Elenis, Angelica Lindén Hirschberg, Alkistis Skalkidou, Stavros I. Iliadis   +9 more
wiley   +1 more source

Menopausal hormone therapy after ovarian cancer: A 10‐year survival analysis in premenopausal women

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
Among premenopausal women surgically treated for ovarian cancer, no difference in 10‐year overall survival was observed between postoperative MHT users and non‐users. Young ovarian cancer survivors should be recommended MHT after surgically induced menopause.
Åsa Ehlin von Kartaschew, Pernilla Dahm‐Kähler, Kenny Rodriguez Wallberg, Erik Holmberg, Angelique Flöter‐Rådestad   +4 more
wiley   +1 more source

Cytostatic and Non-Apoptotic Effects of Vinorelbine-Based Therapy in 3D Endometrial Cancer Spheroids. [PDF]

Biology (Basel)
Yıldırım B, Biltekin B, Karalök MH, Bilir A.   +3 more
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Predictive value of IGF2BP2 for endometrial cancer recurrence: a multicenter study. [PDF]

Front Oncol
Xiong J, Jiang P, Bai X, Tu Y, Tian C, Gong C, Gong Y, Hou L, Zhao L, Yuan R.   +9 more
europepmc   +1 more source

TONSL Promotes Hepatocellular Carcinoma Progression by Inhibiting Apoptosis Through Homologous Recombination Repair

Cancer Science, EarlyView.
In hepatocellular carcinoma, the 8q24.3 locus is frequently amplified and is associated with tumor‐specific overexpression of TONSL. TONSL promotes homologous recombination repair through RAD51, limits γH2AX accumulation and apoptosis, supports tumor growth, and its loss increases sensitivity to poly (ADP‐ribose) polymerase (PARP) inhibition.
Akinori Tsujimoto, Hajime Otsu, Takashi Ofuchi, Tomohiko Ikehara, Kosuke Hirose, Shohei Shibuta, Kazuki Omachi, Yu Takahashi, Yuya Ono, Satoshi Higuchi, Takanari Tatsumi, Kiyotaka Hosoda, Qingjiang Hu, Yusuke Yonemura, Takaaki Masuda, Masayuki Sho, Koshi Mimori   +16 more
wiley   +1 more source

The Concept of "Platinum Sensitivity" in Endometrial Cancer. [PDF]

Cancers (Basel)
Nagao S, Fujikawa A, Imatani R, Tani Y, Matsuoka H, Ida N, Haraga J, Ogawa C, Nakamura K, Masuyama H.   +9 more
europepmc   +1 more source

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

Clinical Endocrinology, EarlyView.
ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley   +1 more source